Professor Nick Pavlakis
Dr David Chan
Cancer experts inform national guidelines A collection of expert clinician researchers from the Northern Sydney Local Health District (NSLHD) have had a key role in the development of new national guidelines for the treatment of neuroendocrine tumours. The COSA NET guidelines provide information for oncologists, health care providers and patients regarding the latest evidence- informed practice. The new recommendations replace the previous ones drafted more than 10 years ago and The guidelines have been developed by Australia’s leading clinical and academic experts, including NSLHD clinicians Drs Nick Pavlakis, Jas Samra, Rory Clifton-Bligh, David Chan and Richie Maher. Dr Pavlakis said our team contributed to the new guidelines by drawing on our expertise in nuclear medicine, systemic therapies, surgery, interventional radiology and our clinical trial experience. “We are confident the new
Centre of Excellence, one of just three centres in the southern hemisphere. Dr Chan said the accreditation is a testament to the exceptional team of clinicians, surgeons, nurses, allied health professionals and researchers at the hospital. “It’s a credit to a very large number of teams, from medical oncology, radiology and surgery to genetics, palliative care and nutrition,” he said. “It means patients can have confidence that they are receiving the very best care in the world, and that their treatment will be in line with the latest international advances.” To access the new guidelines for the treatment of neuroendocrine tumours: https://app.magicapp. org/#/guideline/7724
reflect the significant advances in neuroendocrine tumour treatment over that time. There’s new information about Multiple Endocrine Neoplasia 1, familial NET syndromes and information about supportive care.
guidelines will provide tremendously valuable,
evidenced-based information in a format which is easy to access and adopt,” he said. In recent years, Sydney Theranostics North–based at Royal North Shore Hospital was named a Neuroendocrine Tumour
8
KOLLINGNEWS | FEBRUARY 2024
Made with FlippingBook - professional solution for displaying marketing and sales documents online